Venrock Healthcare Capital Par acquires Lycia Therapeutics stock
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Venrock Healthcare Capital Par purchased 1,000 shares of Lycia Therapeutics stock on October 29th at an average cost of $26.33 per share, totaling $26,330.00. This acquisition was disclosed in a document filed with the SEC. The firm has made several other recent purchases of the stock, including 1,952,705 shares on October 26th.
From themarketsdaily.com
Why it matters
The purchase increased Venrock Healthcare Capital Par's ownership of Lycia Therapeutics. Following the transaction, the insider held 6,841,233 shares, valued at $180,129,664.89, which represents a 0.01% increase in their stake.
Lycia Therapeutics began trading on the Nasdaq stock exchange after being founded in part by Carolyn Bertozzi.
From themarketsdaily.com